Enhancing IL-12 secretion can improve the effectiveness of PD-1 inhibitors, suggesting that a combination therapy involving IL-12 cytokine and PD-1 inhibitors may represent an effective strategy for enhancing cancer immunotherapy [12]. The gene discussed is PDCD1; the disease is cancer.